Stocks-CRSP-CRISPR Therapeutics AG

CRSP CRISPR Therapeutics AG

54.50 0.16 (0.29%)
Invest
Invest
1.53% Past Week
Created with Highcharts 4.2.7 /Highstock 4.2.7
Market Cap
4.27B
Day’s Range
52.52
-
54.56
52W Range
42.47
-
86.71
Volume (3M)
1.05M
Price-Earnings Ratio
22.59
Revenue
14.09M

CRISPR Therapeutics AG Latest News

View All
Top Discussions
MarketUpdates
Edited
$CRSP (CRISPR Therapeutics AG) Q4 2022 earnings report is expected to be released
14
FEB
REPORTS
CRISPR Therapeutics AG Q4 2022 earnings report is expected to be released after market open
Notify me
CRSP
CRSP
CRISPR Therapeutics AG
54.50
0.16
(0.29%)
Trade
CRSP
CRISPR Therapeutics AG
54.34
0.16 (0.29%)
Trade
MarketUpdates
Edited
$CRSP (CRISPR Therapeutics AG) Q4 2022 earnings report is expected to be released
CRSP
CRISPR Therapeutics AG
54.34
0.16 (0.29%)
Trade
HegelHernandez
Society for Immunotherapy of Cancer’s (SITC) 37th Annual Meeting (SITC 2022) about to start and $CRSP (CRISPR Therapeutics AG) knows it. No better time to capitalize on this low priced stocks before they announced the results 🧑‍⚕️
CRSP
CRISPR Therapeutics AG
54.34
0.16 (0.29%)
Trade
HegelHernandez
Today #SITC2022 Annual meeting (Society for #Immunotherapy of Cancer) starts and some top abstracts for press released are from $MRK (Merck & Co.) $BMY (Bristol-Myers Squibb Co) ft. low price stocks from $IOVA (Iovance Biotherapeutics Inc.) $CRSP (CRISPR Therapeutics AG) $FATE (Fate Therapeutics Inc)... Show More
HegelHernandez
Edited
Today #SITC2022 Annual meeting (Society for Immunotherapy of Cancer) starts and some top abstracts released in press are from $MRK (Merck & Co.) $BMY (Bristol-Myers Squibb Co) $IOVA (Iovance Biotherapeutics Inc.) $CRSP (CRISPR Therapeutics AG) $FATE (Fate Therapeutics Inc) $SGEN (Seagen Inc) . Time... Show More

About CRISPR Therapeutics AG

With headquarters in Zug, Switzerland, CRISPR Therapeutics AG (CRSP) is a gene-editing company. Founded in 2013, the firm develops gene-based medicines to treat patients with serious diseases. As of August 2020, the company was working on other programmes, including hemoglobinopathies, immuno-oncology, regenerative medicine and in vivo approaches. The company has offices in San Francisco, California and Cambridge, Massachusetts in the US, as well as an office in Switzerland and a business office in London. Trading on the NASDAQ stock exchange, the ticker CRSP has been assigned to CRISPR Therapeutics AG. From October 2016 to August 2020, the CRSP share price reached a low of $11.63 (February 2017) and rose to a high of $97.82 (July 2020). The company makes use of CRISPR/Cas9 gene-editing technology to modify, delete or correct specific regions of human DNA. This technology was co-invented by Dr Emmanuelle Charpentier, one of CRISPR Therapeutics AG's scientific founders. Genes are edited by precisely cutting DNA and allowing natural DNA repair processes to complete the job. CRISPR Therapeutics AG's lead programme targets β-thalassemia and sickle cell disease. It entered clinical testing in August 2020. Track the CRSP instrument by adding it to your eToro watchlist now and diversify your portfolio with this medical research company.
473
Employees
Zug, Zug, US
HQ
2013
Founded
Samarth Kulkarni, PhD
CEO
Show More

Upcoming Earnings

14
FEB
REPORTS
CRISPR Therapeutics AG Q4 2022 earnings report is expected to be released after market open

ESG: A New Source of Insight

Get insight into a company's sustainability using ESG (environmental, social, and governance) scores.
0
100
51
Medium
Industry 
Avg. 45 
38
Environment
48
Social
59
Governance

People Also Bought